Historique
Périodique
Hepatic fibrosis: molecular mechanisms and drug targets
(La fibrose hépatique : mécanismes moléculaires et cibles médicamenteuses.)
Auteur(s) :
LOTERSZTAJN, S. ;
JULIEN, B. ;
TEIXEIRA-CLERC, F. ;
GRENARD, P. ;
MALLAT, A.
Année
2005
Page(s) :
605-628
Sous-type de document :
Revue de la littérature / Literature review
Langue(s) :
Anglais
ISBN :
0362-1642
Refs biblio. :
131
Domaine :
Drogues illicites / Illicit drugs
Discipline :
PAT (Pathologie organique / Organic pathology)
Thésaurus mots-clés
FOIE
;
FIBROSE
;
CIRRHOSE
;
BIOLOGIE
;
CANNABINOIDES
;
PHYSIOLOGIE
;
MODELE
;
BIOCHIMIE
Note générale :
Annual Review of Pharmacology and Toxicology, 2005, 45, 605-628
Résumé :
Liver fibrosis is the common response to chronic liver injury, ultimately leading to cirrhosis and its complications, portal hypertension, liver failure, and hepatocellular carcinoma. Efficient and well-tolerated antifibrotic drugs are currently lacking, and current treatment of hepatic fibrosis is limited to withdrawal of the noxious agent. Efforts over the past decade have mainly focused on fibrogenic cells generating the scarring response, although promising data on inhibition of parenchymal injury and/or reduction of liver inflammation have also been obtained. A large number of approaches have been validated in culture studies and in animal models, and several clinical trials are underway or anticipated for a growing number of molecules. This review highlights recent advances in the molecular mechanisms of liver fibrosis and discusses mechanistically based strategies that have recently emerged. (Author' s abstract)
Affiliation :
Unite INSERM 581 Hôpital Henri Mondor, 94010 Créteil.
France. France.
France. France.
Cote :
A03056